WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H319751
CAS#: 625115-52-8
Description: Nelociguat, also known as BAY60-4552, is a soluble guanylate cyclase stimulator (sGC stimulator). Soluble guanylate cyclase (sGC) is a key enzyme in the nitric oxide (NO) signalling pathway. On binding of NO to its prosthetic haem group, sGC catalyses the synthesis of the second messenger cyclic guanosine monophosphate (cGMP), which promotes vasodilation and inhibits smooth muscle proliferation, leukocyte recruitment, platelet aggregation and vascular remodelling through a number of downstream mechanisms.
Hodoodo Cat#: H319751
Name: Nelociguat
CAS#: 625115-52-8
Chemical Formula: C19H17FN8O2
Exact Mass: 408.15
Molecular Weight: 408.397
Elemental Analysis: C, 55.88; H, 4.20; F, 4.65; N, 27.44; O, 7.84
Synonym: BAY60-4552; BAY 60-4552; BAY-60-4552; BAY604552; BAY-604552; BAY 604552; Nelociguat
IUPAC/Chemical Name: methyl (4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)carbamate
InChi Key: FTQHGWIXJSSWOY-UHFFFAOYSA-N
InChi Code: 1S/C19H17FN8O2/c1-30-19(29)24-14-15(21)25-17(26-16(14)22)13-11-6-4-8-23-18(11)28(27-13)9-10-5-2-3-7-12(10)20/h2-8H,9H2,1H3,(H,24,29)(H4,21,22,25,26)
SMILES Code: FC1=CC=CC=C1CN2N=C(C3=NC(N)=C(NC(OC)=O)C(N)=N3)C4=CC=CN=C42
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 408.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Zhao X, Wang Z, Wang Y, Zhang H, Blode H, Yoshikawa K, Becker C, Unger S, Frey R, Cui Y. Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study. Clin Pharmacokinet. 2015 Oct 27. [Epub ahead of print] PubMed PMID: 26507720.
2: Stasch JP, Schlossmann J, Hocher B. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Curr Opin Pharmacol. 2015 Apr;21:95-104. doi: 10.1016/j.coph.2014.12.014. Epub 2015 Jan 31. Review. PubMed PMID: 25645316.
3: Gnoth MJ, Hopfe PM, Czembor W. Determination of riociguat and its major human metabolite M-1 in human plasma by stable-isotope dilution LCMS/MS. Bioanalysis. 2015;7(2):193-205. doi: 10.4155/bio.14.257. PubMed PMID: 25587836.
4: Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol. 2013;218:279-313. doi: 10.1007/978-3-642-38664-0_12. Review. PubMed PMID: 24092345.
5: Albersen M, Linsen L, Tinel H, Sandner P, Van Renterghem K. Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. J Sex Med. 2013 May;10(5):1268-77. doi: 10.1111/jsm.12095. Epub 2013 Feb 19. PubMed PMID: 23421435.
6: Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ, Morgan LA, Maniscalco K, Olzinski AR, Ballard VL, Herry K, Grondin P, Dodic N, Mirguet O, Bouillot A, Gellibert F, Coatney RW, Lepore JJ, Jucker BM, Jolivette LJ, Willette RN, Schnackenberg CG, Behm DJ. Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress. Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. PubMed PMID: 22783192; PubMed Central PMCID: PMC3389674.
7: Mirone V, Verze P. Are we finally on the right track in treating "difficult" erectile dysfunction patients? Eur Urol. 2011 Nov;60(5):1027-8. doi: 10.1016/j.eururo.2011.08.013. Epub 2011 Aug 16. PubMed PMID: 21893378.
8: Oudot A, Behr-Roussel D, Poirier S, Sandner P, Bernabé J, Alexandre L, Giuliano F. Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur Urol. 2011 Nov;60(5):1020-6. doi: 10.1016/j.eururo.2011.07.052. Epub 2011 Jul 30. PubMed PMID: 21839578.
